INNOCRINPHARMA.COM

Innocrin

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. We are a privately held, clinical stage pharmaceutical company that develops novel, best-in-class oral CYP17 lyase inhibitors for the treatment of castration-resistant prostate cancer (CRPC) and potentially in other hormonally-driven conditions such as breast cancer, endometriosis, or congenital adrenal hyperlplasia.

http://www.innocrinpharma.com/

OVERVIEW OF innocrinpharma.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

11

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR INNOCRINPHARMA.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

December

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Saturday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 3.6 out of 5 with 8 reviews

5 star

4

4 star

1

3 star

1

2 star

0

1 star

2

Hey there! Start your review of innocrinpharma.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

FAVICON PREVIEW

16x16
32x32

CONTACTS AT INNOCRINPHARMA.COM

Domains By Proxy, LLC

Registration Private

Domain●●●●●●xy.com

14747 N Norths●●●●●●●●●●●●●●e 111, PMB 309

Sco●●●ale , Arizona, 85260

UNITED STATES

1480●●●●2599

1480●●●●2598

IN●●●●●●●●●●●●●●●●@domainsbyproxy.com

View this contact

Domains By Proxy, LLC

Registration Private

Domain●●●●●●xy.com

14747 N Norths●●●●●●●●●●●●●●e 111, PMB 309

Sco●●●ale , Arizona, 85260

UNITED STATES

1480●●●●2599

1480●●●●2598

IN●●●●●●●●●●●●●●●●@domainsbyproxy.com

View this contact

Domains By Proxy, LLC

Registration Private

Domain●●●●●●xy.com

14747 N Norths●●●●●●●●●●●●●●e 111, PMB 309

Sco●●●ale , Arizona, 85260

UNITED STATES

1480●●●●2599

1480●●●●2598

IN●●●●●●●●●●●●●●●●@domainsbyproxy.com

View this contact

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

DOMAIN REGISTRATION INFORMATION

REGISTERED: 2014 June 25
UPDATED: 2014 June 25
EXPIRATION: EXPIRED REGISTER THIS DOMAIN

BUY YOUR DOMAIN

DOMAIN AGE

11

YEARS
4

MONTHS
15

DAYS

NAME SERVERS

1: ns69.domaincontrol.com
2: ns70.domaincontrol.com

REGISTRAR

GODADDY.COM, LLC

WHOIS : whois.godaddy.com

REFERRED : http://registrar.godaddy.com

CONTENT

PAGES IN
THIS WEBSITE

11

SSL

EXTERNAL LINKS

3

SITE IP

37.60.253.233

LOAD TIME

0 sec

SCORE

6.2

PAGE TITLE

Innocrin | innocrinpharma.com Reviews

<META> DESCRIPTION

We discover and develop novel, best-in-class inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. We are a privately held, clinical stage pharmaceutical company that develops novel, best-in-class oral CYP17 lyase inhibitors for the treatment of castration-resistant prostate cancer (CRPC) and potentially in other hormonally-driven conditions such as breast cancer, endometriosis, or congenital adrenal hyperlplasia.

<META> KEYWORDS

1 go to top

2 about us

3 management

4 board of directors

5 product development

6 our programs

7 clinical trials

8 our pipeline

9 partnering

10 investors

CONTENT

Page content here

KEYWORDS ON PAGE

go to top,about us,management,board of directors,product development,our programs,clinical trials,our pipeline,partnering,investors,news,conferences,directions,careers,innocrin,search for,pipeline,terms of use

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Innocrin | innocrinpharma.com Reviews

https://innocrinpharma.com

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. We are a privately held, clinical stage pharmaceutical company that develops novel, best-in-class oral CYP17 lyase inhibitors for the treatment of castration-resistant prostate cancer (CRPC) and potentially in other hormonally-driven conditions such as breast cancer, endometriosis, or congenital adrenal hyperlplasia.

INTERNAL PAGES

innocrinpharma.com

1

Conferences | Innocrin

http://innocrinpharma.com/investors/conferences

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. PCF’s 23rd Annual Scientific Retreat. October 27-29, 2016. William Moore, CEO. Biocentury Biotech Industry Newsmakers Conference. September 9-10, 2016. New York, NY. William Moore, CEO. Canaccord Genuity Growth Conference. August 10-11, 2016. William Moore, CEO. American Society of Clinical Oncology (ASCO). June 3-7, 2016. Pdf: view poster here. March 1-2, 2016. William Moore, CEO.

2

Partnering | Innocrin

http://innocrinpharma.com/partnering

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. We value and wish to hear from creative partners who share our motivation to accelerate seviteronel development for the treatment of castration-resistant prostate cancer and breast cancer. We also have interest to hear from parties who would like more information on our broad CYP17 lyase inhibitor pipeline for the treatment of oncology and non-oncology indications.

3

About Us | Innocrin

http://innocrinpharma.com/about-us

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. CYP17 lyase inhibitors have high commercial potential for the treatment of CRPC and breast cancer as well as other cancers that utilize androgens as growth factors (e.g., ovarian, bladder, hepatocellular, and lung). Selective CYP17 lyase inhibitors also have potential for the treatment of non-oncologic syndromes that are due to the condition of androgen excess.

4

Management | Innocrin

http://innocrinpharma.com/about-us/management

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. William R. Moore, Ph.D. President, CEO and Director. William Moore, Ph.D. Joel Eisner, Ph.D. Vice President, Clinical Operations. Ronald A. Fleming, Pharm.D. Vice President, Translational Research. Michael Kurman, MD. Charles F. Osborne, Jr. CPA. Chief Financial Officer and Corporate Secretary. Aaron (Ron) Weitzman, MD. Sr Medical Prostate Cancer Adviser.

5

News | Innocrin

http://innocrinpharma.com/news

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. May 12, 2016. Innocrin Pharmaceuticals Inc. Begins Phase 2 Breast Cancer Study and Expands 2 Phase 2 Prostate Cancer Studies. January 7, 2016. Innocrin Pharmaceuticals, Inc. Granted Fast Track Designation by FDA. July 1, 2015. Charles Osborne joins Innocrin Pharmaceuticals as CFO. May 27, 2015. April 14, 2015. Innocrin Pharmaceuticals, Inc. Raises $28 Million in Series D Financing.

UPGRADE TO PREMIUM TO VIEW 6 MORE

TOTAL PAGES IN THIS WEBSITE

11

LINKS TO THIS WEBSITE

eshelmanventures.com

Our Portfolio | Eshelman Ventures LLC of Wilmington NC

http://www.eshelmanventures.com/portfolio

Eshelman Ventures, LLC. Eshelman Ventures, LLC. Support Group International (SGI) delivers full-spectrum support services and products globally, specializing in solutions to complex requirements for governmental, commercial, and non-government organizations. Focus is on security, logistics, and medical support. SGI combines the capabilities and capacity of several supporting companies with extensive international experience, leadership, and unique products for their clients. Carbon3D, a Silicon Valley ba...

intersouth.com

Portfolios Innocrin Pharmaceuticals Intersouth Partners

http://www.intersouth.com/portfolios/innocrin-pharmaceuticals

Experienced early-stage venture capital firm. News & Events. Research Triangle Park, NC. CEO: William R. Moore. Richard Kent, M.D. Innocrin Pharmaceuticals Inc. Begins Phase 2 Breast Cancer Study and Expands 2 Phase 2 Prostate Cancer Studies. Innocrin Pharmaceuticals, Inc. Granted Fast Track Designation by FDA for VT-464 Treatment of Patients with Metastatic Castrate-resistant Prostate Cancer. Innocrin Pharmaceuticals, Inc. Raises $28 Million in Series D Financing.

UPGRADE TO PREMIUM TO VIEW 1 MORE

TOTAL LINKS TO THIS WEBSITE

3

OTHER SITES

innocrest.com

InnoCrest

December 12th, 2014. Internship Programme for Mobile Communication (RF). Participant will be exposed to real world of RF engineering for mobile communication including field measurement activity, field. Measurement analysis, statistic performance analysis and network optimisation. The soft skills enhancement programme will be part of the internship programme to prepare the undergraduate to become professional and valuable to the industry. Internship programme for Mobile Communication duration is ...Perfo...

innocrete.co.th

InnoCrete: INNOCRETE…Innovation set in concrete

News & Update. INNOCRETE…Innovation set in concrete. นว ตกรรม เพ อความงามเสม อนธรรมชาต. Stamped Concrete … Multi Solution for Design. จ งตอบสนองการออกแบบได ท งงานตกแต งภายในและภายนอก ด วยลวดลาย ห นกว า 40 ร ปแบบ และส มาตรฐานกว า 40 ส ท งน สามารถส งผล ต ตามแบบ เพ อความพอใจ และเป นเอกล กษณ ของโครงการ ท งงานถนน ทางเด น ระเบ ยง ทางเด นรอบสระว ายน ำ ลานอเนกประสงค งานสะพาน พ นโชว ร ม และท กจ นตนาการการออกแบบ. Stamped Concrete … Multi Solution for Design. L News and update.

innocrete.com

InnoCrete

Office: 303.471.2746. Mobile: 303.888.8182. Is a Highlands Ranch company specializing in all aspects of outdoor living. Stamped Concrete, Gas Fire Pits, Stone Seating Walls, Outdoor Kitchens and much more! Stamped Concrete, A Fresh New Look. Stamped concrete installed by Inno-Crete. Provides a fresh new look, inside or out. And, with so many colors and patterns. Link to patterns page). To choose from, it is easy to create a perfect compliment to any home. Site designed by Just Incredible Design, LLC.

innocrew.com

이노크루

innocrex.com

Innocrex

Transforming organizations by managing for INNOvation, CReativity, and EXcellence. Transformer les organisations grâce à la gestion de l'INNOvation, de la CRéativité, et de l'EXcellence.

innocrinpharma.com

Innocrin

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. We are a privately held, clinical stage pharmaceutical company that develops novel, best-in-class oral CYP17 lyase inhibitors for the treatment of castration-resistant prostate cancer (CRPC) and potentially in other hormonally-driven conditions such as breast cancer, endometriosis, or congenital adrenal hyperlplasia.

innocrinpharma.org

Innocrin

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. Innocrin is a privately held, clinical-stage pharmaceutical company that discovers and develops novel, best-in-class oral selective inhibitors of CYP17 lyase, a validated target for the treatment of advanced breast and prostate cancer. We are developing oral, conveniently administered CYP17 lyase inhibitors for the benefit of patients with hormonally-driven diseases or conditions.

innocrisa.com

innocrisa.com - Inicio

Abarcamos todos los productos correspondientes al Vidrio y Aluminio. Canceles de Baño. Los Fabricamos e instalamos con los mejores materiales como son:. Tecnología en Herrajes e YBJ. Innovación en Cristal, SA de CV.

innocrit.com

INNOCRIT.COM

innocrm.com

InnoCRM - New Devise/Session

innocrop.com

Innocrop Consulting • Pages

Welcome on the web site of Innocrop Consulting. Peter Schreurs, e-mail: peterschreurs@innocrop.nl. Herman Hermans, e-mail: hermanhermans@innocrop.nl. Herman Keijsers, e-mail: hermankeijsers@innocrop.nl.